USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Discovery of New Targeted Therapies Will Replace Conventional Therapies
This study assesses marketed and in-research products and combination regimens for the lung cancer therapeutics market. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented by their mechanism of action against cancer. Cost-effective treatments and targeted therapies are the key unmet needs of the market.
Executive Summary
Executive Summary (continued)
Executive Summary (continued)
Methodology and Scope
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Recent Market Developments
Companies to Watch
Key Merger, Acquisition, and Partnership Assessment
Game-changing Strategies
Epidemiology
Epidemiology (continued)
Epidemiology (continued)
Competitive Landscape—Marketed and Pipeline Drugs in Pre-registration and Phase 3
Competitive Landscape—Pipeline Drugs in Phase 1 and Phase 2
Timeline of Product Launches/Approval
Timeline of Patent Expiries
Competitive Landscape—Pivotal Clinical Trials
Competitive Landscape—Pivotal Clinical Trials (continued)
Marketed Products Synopsis
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Pipeline Synopsis
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Product Dashboard: Tarceva® (Erlotinib)—Roche Group
Product Dashboard: Gilotrif® (Afatinib)—Boehringer Ingelheim
Product Dashboard: Avastin® (Bevacizumab)—Genentech Inc. (Roche Group)
Product Dashboard: Alimta® (Pemetrexed)—Eli Lilly and Company
Product Dashboard: XALKORI® (Crizotinib)—Pfizer Inc.
Product Dashboard: AP26113—Ariad Pharmaceuticals, Inc.
Product Dashboard: Necitumumab—Eli Lilly and Company
Product Dashboard: Nivolumab—Bristol-Myers Squibb Company and Ono Pharmaceutical
Conclusions
Legal Disclaimer
About Lung Cancer
About Lung Cancer (continued)
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related industry research
17 Sep 2026 | Asia Pacific | Frost Radar
Frost Radar™: Facility Management in Malaysia, 2026
Malaysia's facility management (FM) market is transitioning from labor-intensive, compliance-driven service delivery to technology-enabled, outcome-oriented, and sustainability-integrated operating models. Competitive differentiation increasingly depends on providers’ ability to combine integrated F...
17 Sep 2026 | Global | Market Research
Growth Opportunities in the Western Europe Consumer eSIM Market, 2026–2029
The consumer eSIM market in Western Europe is growing steadily, supported by the rising availability of eSIM-capable devices, particularly smartphones, and expanding travel-related use cases. However, commercialization has yet to translate into mass adoption. Despite Apple’s global launch of an eSIM...
17 Sep 2026 | Asia Pacific | Frost Radar
Frost Radar™: ASEAN Warehouse Automation System Providers, 2026
Warehouse automation has moved from a discretionary capital project to a core operating capability. ASEAN operators are redesigning fulfillment networks around smaller orders, shorter delivery windows, broader stock keeping unit (SKU) ranges, and sharper demand volatility. Manual operations remain v...
16 Sep 2026 | North America | Customer Research
US Automotive Technicians’ Choice Survey, 2025
The 2025 US Automotive Technicians’ Choice study is an insightful voice-of-customer survey that highlights the tool preferences of automotive aftermarket service technicians. The survey of 400 automotive technicians across the United States used a combination of computer-assisted telephone and compu...
16 Sep 2026 | Global | Market Research
Apple Performance Tracker, Q1 2026
This Frost & Sullivan tracker provides metrics on Apple's quarterly performance (for both unit sales and revenues) for iPads, iPhones, Macs, and other products, such as iPods, Apple TVs, Beats Electronics, and Apple-branded and third-party accessories. It includes historical quarterly data for all t...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Sumedha Pareek |
| WIP Number | MAC3-01-00-00-00 |
| Is Prebook | No |
A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market
$3,950.00
Special Price $2,962.50 save 25 %